Close Menu

Trovagene

The company has seen promising activity for the drug in KRAS-mutated metastatic colorectal cancer, and biomarker-defined patient subgroups with castration-resistant prostate cancer and AML.

Data from an ongoing study suggests that the drug, combined with an androgen receptor signaling inhibitor, may be efficacious in a particularly hard to treat form of prostate cancer.

In the 44-patient study, onvansertib will be studied in combination with Avastin and FOLFIRI in the second-line metastatic colorectal cancer setting.